Company
Headquarters: Andover, MA, United States
Employees: 148
CEO: Dr. Waleed H. Hassanein
$4.93 Billion
USD as of July 1, 2024
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
TransMedics Group, Inc. has the following listings and related stock indices.
Stock: NASDAQ: TMDX wb_incandescent